tanshinone ii a has been researched along with N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide in 2 studies
| Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) | Studies (N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide) | Trials (N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide) | Recent Studies (post-2010) (N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide) |
|---|---|---|---|---|---|
| 61 | 0 | 41 | 12 | 0 | 11 |
| Protein | Taxonomy | tanshinone ii a (IC50) | N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide (IC50) |
|---|---|---|---|
| Spike glycoprotein | Betacoronavirus England 1 | 0.05 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 0.05 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 0.05 | |
| Calpain-1 catalytic subunit | Homo sapiens (human) | 0.0041 | |
| Procathepsin L | Homo sapiens (human) | 0.0194 | |
| Cathepsin B | Homo sapiens (human) | 0.0041 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 0.05 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 0.05 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 0.0402 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.0726 | |
| Cathepsin K | Homo sapiens (human) | 0.0041 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 0.05 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 review(s) available for tanshinone ii a and N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
1 other study(ies) available for tanshinone ii a and N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |